Login to get immediate access to this content.
LoginSpeaker: Francesco Sclafani, Belgium
Abstract discussed:
- LBA2 - Efficacy interim analysis of REGINA, a phase II trial of neoadjuvant regorafenib (Rego), nivolumab (Nivo), and short-course radiotherapy (SCRT) in stage II-III rectal cancer (RC) - Watch the session from ESMO Gastrointestinal Cancers Congress 2024 now
The speakers and studies featured in this video series were selected independently by ESMO.
Published July 2024